AI Engines For more Details: Perplexity Kagi Labs You
Hyperlipidemia: Ciprofibrate is indicated for the treatment of various forms of hyperlipidemia, including hypercholesterolemia (high levels of cholesterol) and hypertriglyceridemia (high levels of triglycerides). It belongs to a class of medications known as fibric acid derivatives or fibrates, which work by activating peroxisome proliferator-activated receptors (PPARs) in the liver and peripheral tissues. This activation leads to increased lipolysis of triglycerides and enhanced clearance of triglyceride-rich lipoproteins from the bloodstream, resulting in reduced levels of triglycerides and, to a lesser extent, LDL cholesterol.
Mixed Dyslipidemia: Ciprofibrate may be used to treat mixed dyslipidemia, a condition characterized by elevated levels of both cholesterol and triglycerides in the blood. It can help improve the lipid profile by reducing triglyceride levels and increasing HDL cholesterol levels, leading to a decrease in the risk of cardiovascular events such as heart attacks and strokes.
Primary Prevention of Cardiovascular Disease: Ciprofibrate may be used as part of a comprehensive approach to reduce the risk of cardiovascular disease in individuals with dyslipidemia who have not yet experienced a cardiovascular event. By improving lipid parameters, particularly reducing triglycerides and increasing HDL cholesterol, ciprofibrate may help lower the risk of atherosclerosis and its complications.
Secondary Prevention of Cardiovascular Events: Ciprofibrate may also be used for secondary prevention in individuals with a history of cardiovascular events, such as myocardial infarction (heart attack) or stroke, who have persistent dyslipidemia despite lifestyle modifications and other interventions. By optimizing lipid levels, ciprofibrate may reduce the risk of recurrent cardiovascular events and improve overall prognosis.
Adverse Effects: Common side effects of ciprofibrate may include gastrointestinal disturbances (such as abdominal pain, nausea, diarrhea), muscle pain or weakness (myopathy), elevated liver enzymes, and, rarely, gallstones or pancreatitis. Patients taking ciprofibrate should be monitored regularly for signs of myopathy (e.g., unexplained muscle pain, tenderness, weakness) and liver function abnormalities.
Drug Interactions: Ciprofibrate may interact with other medications, particularly those metabolized by the cytochrome P450 system, such as statins (cholesterol-lowering drugs), anticoagulants (blood thinners), and certain antibiotics. Concurrent use of ciprofibrate with these medications may increase the risk of drug interactions and adverse effects, necessitating close monitoring and dose adjustments as needed.
Contraindications: Ciprofibrate is contraindicated in individuals with severe liver or kidney impairment, gallbladder disease, or a history of hypersensitivity to fibrates or any of the components of the medication. It should be used with caution in elderly patients and those with a history of myopathy or rhabdomyolysis (muscle breakdown).
| Rank | Probiotic | Impact |
|---|---|---|
| species | Bacteroides uniformis | Reduces |
| species | Escherichia coli | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.8 | 0.8 | |
| ADHD | 2.3 | 0.3 | 6.67 |
| Age-Related Macular Degeneration and Glaucoma | 0.5 | 0.4 | 0.25 |
| Allergic Rhinitis (Hay Fever) | 2.2 | 0.8 | 1.75 |
| Allergies | 2.5 | 1.2 | 1.08 |
| Allergy to milk products | 1.2 | 1.3 | -0.08 |
| Alopecia (Hair Loss) | 0.3 | 0.3 | |
| Alzheimer's disease | 3.1 | 4.6 | -0.48 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.6 | 0.4 | 3 |
| Ankylosing spondylitis | 2.4 | 1.2 | 1 |
| Anorexia Nervosa | 0.7 | 2.1 | -2 |
| Antiphospholipid syndrome (APS) | 1.7 | 0.3 | 4.67 |
| Asthma | 2.5 | 1.1 | 1.27 |
| Atherosclerosis | 1.6 | 1.5 | 0.07 |
| Atrial fibrillation | 2 | 2.9 | -0.45 |
| Autism | 5.2 | 5.6 | -0.08 |
| Autoimmune Disease | 0.9 | 0.5 | 0.8 |
| Barrett esophagus cancer | 0.3 | 0.3 | 0 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 1.4 | 1.4 | |
| Bipolar Disorder | 1.6 | 0.8 | 1 |
| Brain Trauma | 0.6 | 0.8 | -0.33 |
| Breast Cancer | 0.4 | 0.4 | |
| Cancer (General) | 0.6 | 0.6 | |
| Carcinoma | 2.8 | 1.3 | 1.15 |
| Celiac Disease | 2.4 | 1.3 | 0.85 |
| Cerebral Palsy | 0.6 | 0.8 | -0.33 |
| Chronic Fatigue Syndrome | 2 | 3.8 | -0.9 |
| Chronic Kidney Disease | 2.3 | 2.1 | 0.1 |
| Chronic Lyme | 0.8 | -0.8 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.4 | 1.4 | 0 |
| Chronic Urticaria (Hives) | 1.2 | 1 | 0.2 |
| Coagulation / Micro clot triggering bacteria | 1.7 | 0.8 | 1.13 |
| Cognitive Function | 1.3 | 1.1 | 0.18 |
| Colorectal Cancer | 4.5 | 2.1 | 1.14 |
| Constipation | 1.1 | 0.5 | 1.2 |
| Coronary artery disease | 2.4 | 2.5 | -0.04 |
| COVID-19 | 4.5 | 5.8 | -0.29 |
| Crohn's Disease | 5.4 | 3.5 | 0.54 |
| Cushing's Syndrome (hypercortisolism) | 0.5 | -0.5 | |
| cystic fibrosis | 1 | 0.8 | 0.25 |
| d-lactic acidosis (one form of brain fog) | 0.4 | 0.4 | |
| deep vein thrombosis | 1.7 | 1.1 | 0.55 |
| Denture Wearers Oral Shifts | 0.3 | 0.3 | |
| Depression | 4.9 | 5.8 | -0.18 |
| Dermatomyositis | 0.3 | 0.3 | |
| Eczema | 1.8 | 0.7 | 1.57 |
| Endometriosis | 2.3 | 1.5 | 0.53 |
| Eosinophilic Esophagitis | 0.3 | 0.3 | 0 |
| Epilepsy | 2.5 | 1.3 | 0.92 |
| erectile dysfunction | 1.2 | 1.2 | |
| Fibromyalgia | 1.5 | 1.7 | -0.13 |
| Functional constipation / chronic idiopathic constipation | 3.7 | 2.6 | 0.42 |
| gallstone disease (gsd) | 2.4 | 0.8 | 2 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.9 | 0.3 | 2 |
| Generalized anxiety disorder | 2.7 | 0.9 | 2 |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 0.6 | 0.3 | 1 |
| Graves' disease | 1 | 1.7 | -0.7 |
| Gulf War Syndrome | 0.6 | 0.9 | -0.5 |
| Halitosis | 0.9 | 0.3 | 2 |
| Hashimoto's thyroiditis | 1.6 | 0.6 | 1.67 |
| Heart Failure | 2.9 | 1.2 | 1.42 |
| hemorrhagic stroke | 0.7 | 0.7 | |
| Hidradenitis Suppurativa | 1.2 | 1.2 | |
| High Histamine/low DAO | 0.9 | 0.9 | |
| hypercholesterolemia (High Cholesterol) | 0.7 | 0.7 | |
| hyperglycemia | 1 | 0.7 | 0.43 |
| Hyperlipidemia (High Blood Fats) | 0.6 | 0.3 | 1 |
| hypersomnia | 0.6 | -0.6 | |
| hypertension (High Blood Pressure | 2.5 | 2.9 | -0.16 |
| Hypothyroidism | 0.3 | -0.3 | |
| Hypoxia | 1.7 | 1.7 | |
| IgA nephropathy (IgAN) | 1.3 | 2.4 | -0.85 |
| Inflammatory Bowel Disease | 3.8 | 5.7 | -0.5 |
| Insomnia | 0.9 | 1.4 | -0.56 |
| Intelligence | 1.1 | 0.6 | 0.83 |
| Intracranial aneurysms | 1 | 0.6 | 0.67 |
| Irritable Bowel Syndrome | 4.1 | 2.5 | 0.64 |
| ischemic stroke | 1.4 | 1.7 | -0.21 |
| Liver Cirrhosis | 4.4 | 2.3 | 0.91 |
| Long COVID | 4.7 | 3.9 | 0.21 |
| Low bone mineral density | 0.8 | -0.8 | |
| Lung Cancer | 0.9 | 0.9 | |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 0.9 | 0.3 | 2 |
| ME/CFS with IBS | 0.3 | 0.9 | -2 |
| ME/CFS without IBS | 0.9 | 0.3 | 2 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 0.3 | 0.5 | -0.67 |
| Metabolic Syndrome | 5.8 | 3.5 | 0.66 |
| Mood Disorders | 4.3 | 5.3 | -0.23 |
| multiple chemical sensitivity [MCS] | 0.3 | 0.3 | |
| Multiple Sclerosis | 2.7 | 3.5 | -0.3 |
| Multiple system atrophy (MSA) | 0.1 | 0.1 | |
| myasthenia gravis | 0.9 | 0.5 | 0.8 |
| neuropathic pain | 1.7 | -1.7 | |
| Neuropathy (all types) | 0.3 | 2 | -5.67 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.9 | 0.9 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 3.5 | 2.1 | 0.67 |
| NonCeliac Gluten Sensitivity | 0.6 | 0.3 | 1 |
| Obesity | 6.1 | 3.8 | 0.61 |
| obsessive-compulsive disorder | 2.8 | 2.7 | 0.04 |
| Osteoarthritis | 2 | 0.6 | 2.33 |
| Osteoporosis | 1.4 | 0.6 | 1.33 |
| pancreatic cancer | 0.6 | 0.3 | 1 |
| Parkinson's Disease | 4.6 | 4.8 | -0.04 |
| Polycystic ovary syndrome | 4.5 | 1.7 | 1.65 |
| Postural orthostatic tachycardia syndrome | 0.3 | -0.3 | |
| Premenstrual dysphoric disorder | 0.3 | 0.4 | -0.33 |
| primary biliary cholangitis | 0.3 | 1.1 | -2.67 |
| Primary sclerosing cholangitis | 1.4 | 1.3 | 0.08 |
| Psoriasis | 1.5 | 2.8 | -0.87 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 4.7 | 3.1 | 0.52 |
| Rosacea | 0.1 | 0.5 | -4 |
| Schizophrenia | 2.6 | 1.6 | 0.63 |
| scoliosis | 0.7 | 0.3 | 1.33 |
| Sjögren syndrome | 2.2 | 1.2 | 0.83 |
| Sleep Apnea | 0.6 | 1.1 | -0.83 |
| Slow gastric motility / Gastroparesis | 0.7 | 0.7 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.5 | 1.5 | |
| Stress / posttraumatic stress disorder | 1.9 | 1.8 | 0.06 |
| Systemic Lupus Erythematosus | 3.8 | 0.8 | 3.75 |
| Tic Disorder | 0.8 | 0.9 | -0.13 |
| Tourette syndrome | 0.3 | 0.3 | 0 |
| Type 1 Diabetes | 2.4 | 1.3 | 0.85 |
| Type 2 Diabetes | 6.2 | 3.8 | 0.63 |
| Ulcerative colitis | 2.6 | 4 | -0.54 |
| Unhealthy Ageing | 2.7 | 2.2 | 0.23 |
| Vitiligo | 1.4 | 1 | 0.4 |
